1stOncology™: Cancer Intelligence Service – Page 84 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

On May 27, 2026 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reported it will share data demonstrating the utility of Myriad’s Precise MRD (molecular residual disease) test across diverse cancer types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Myriad will share evidence across six poster presentations showcasing the prognostic power of its ultrasensitive MRD assay. Several of the presentations report interim outcomes from the groundbreaking MONSTAR-SCREEN-3 study, led by Dr. Takayuki Yoshino, National Cancer Center Hospital East, Japan. "MONSTAR-SCREEN-3 has demonstrated exceptional performance of Precise MRD across more than a dozen indications," said Dr. Yoshino. "In our presentation, ’Prognostic Impact of MRD Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3,’ we report 97% baseline detection, with 16% of samples detected in the ultrasensitive range. Importantly, patients who were ctDNA-positive at one month post-surgery had significantly worse disease-free survival compared to those who were ctDNA-negative, suggesting that post-surgical ctDNA positivity, including at ultrasensitive levels, is strongly prognostic for recurrence risk."

Other presentations focused on ovarian cancer, gastric cancer, head and neck cancer, and sarcoma also demonstrate the emerging clinical utility of ctDNA as a biomarker of recurrence and therapy response. "Our findings highlight the clear advantage of a whole-genome, personalized MRD approach in capturing clinically meaningful signals at the lowest ctDNA levels," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. "Detecting ctDNA at very low levels consistently across multiple tumor types demonstrates that sensitivity truly matters. Precise MRD may enable a new standard in which ultra-sensitive detection translates directly into earlier, more confident clinical decision-making."

Attendees can meet Dr. Muzzey at the Industry Expert Theater #1 on Sun., May 31 from 9:30 to 10:30 am CDT for an introduction to the Precise MRD Test. The session will cover assay technical details and the clinical evidence across multiple solid tumors, including breast and colorectal cancers, and explore the role of highly sensitive MRD detection in oncology.

Myriad Presentations
Poster 64, abstract 4081: Whole-Genome Sequencing-Based Ultra-sensitive ctDNA Molecular Residual Disease Assessment in Resectable Gastric Cancer: Results from MONSTAR-SCREEN-3
Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sat., May 30, 9:00 am–12:00 pm CDT

Poster 181, abstract 3044: Prognostic Impact of Positivity at Ultra-sensitive ctDNA Levels Using a WGS-based Personalized Assay: A Pan-Cancer Analysis from MONSTAR-SCREEN-3
Poster Session: Developmental Therapeutics
Sat., May 30, 1:30-4:30 pm CDT

Poster 523, abstract 6066: Clinical Validation of Ultra-Sensitive WGS-based MRD Detection in Head and Neck Squamous Cell Carcinoma: Results from MONSTAR-SCREEN-3
Poster Session: Head and Neck Cancer
Sat., May 30, 1:30–4:30 pm CDT

Poster 270, abstract 5604: The Use of Circulating Tumor DNA to Stratify the Risk of Recurrence After Surgical Debulking in Epithelial Ovarian Cancer
Poster Session: Gynecologic Cancer
Mon., June 1, 9:00 am–12:00 pm CDT

Poster 334, abstract 11544: Ultra-Sensitive Whole-Genome Sequencing-Based Molecular Residual Disease Detection in Resectable Sarcoma in MONSTAR-SCREEN-3
Poster Session: Sarcoma
Mon., June 1, 1:30 – 4:30 pm CDT

Poster 501, abstract 10540: Association between physical activity and molecular residual disease clearance in postoperative cancer patients: The SCRUM-MONSTAR LIFELOG study
Poster Session: Prevention, Risk Reduction, and Genetics
Mon., June 1, 2026, 1:30pm – 4:30pm CDT

Conference Highlights
Myriad will welcome attendees to its booth (#25081) during exhibition hours. Myriad tests to be highlighted at the booth include:

Precise MRD (Molecular Residual Disease) Test is a tumor-informed assay that uses whole genome sequencing (WGS) to achieve ultra-sensitivity. This unique assay enables the custom selection of up to 1,000 targeted variants for deep analysis. It has impressive limits of detection and sensitivity.1 The test can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical cancer care, starting immediately after diagnosis and continuing through treatment and surveillance.
MyRisk Hereditary Cancer Test with RiskScore combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk to uncover insights that gene testing alone may not provide, helping offer more information to support patient decisions in breast cancer risk assessment and management.
Prolaris + AI Prostate Cancer Prognostic Test is the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology from Myriad’s partnership with PATHOMIQ AI.

The booth will also feature Myriad’s Biopharma services which are utilized for working in conjunction with Biopharma partners to advance drug development programs from biomarker discovery through CTA, CDx development, worldwide regulatory approval and global commercialization, including:

MyChoice CDx is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO (Free ASCO Whitepaper) guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors.1 By determining comprehensive HRD status, the MyChoice CDx Test helps expand access to targeted therapy in both early and late-line settings.
MSK-ACCESS is a comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK). The test offers noninvasive cancer genomic profiling and disease monitoring using cell-free DNA (cfDNA) obtained from blood and other body fluids. The test is currently available for use in conjunction with Myriad’s Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS.
MSK-IMPACT is a solid tumor test for comprehensive genomic profiling (CGP) which delivers high-resolution profiling of complex biomarkers from DNA and RNA in a single, end-to-end workflow. The test is currently available for use in conjunction with Pharma partnerships for CTA development and CDx utilizing Myriad’s partnership with SOPHiA GENETICS.

Stop by Myriad booth #25081 to learn more or request a dedicated meeting at the show.

About the MONSTAR-SCREEN-3 Study
The MONSTAR-SCREEN-3 is a prospective multicenter study targeting more than 1,100 patients with solid tumors undergoing curative-intent treatment. Personalized panels were constructed using Precise MRD, incorporating up to 1,000 tumor-specific alterations identified through WGS of matched tumor tissue. Serial plasma samples were collected at baseline, post-neoadjuvant treatment (NAT) (when applicable), 1-month (1M) post-surgery, every 3 months in year 1, and every 6 months thereafter up to 2 years. Assay performance was evaluated across multiple cancer types for ctDNA detection and recurrence monitoring.

About Precise MRD
The Precise MRD test provides molecular insights across the cancer care continuum. After diagnosis, the test can help clinicians determine if adjuvant treatment is needed, or if cancer has recurred. Should cancer metastasize in a patient, Precise MRD can provide molecular insights showing whether treatment is working or if a patient’s ctDNA is increasing. For baseline tests, a personalized panel is developed based on a whole-genome sequencing profile of tumor tissue, and then the panel is used to measure the ctDNA level from an initial blood draw. For ongoing monitoring, the panel measures ctDNA levels from samples collected with a frequency based on where patients are in the treatment process. Clinicians will receive an easy-to-read report that shows whether ctDNA was detected or not. If ctDNA is detected, the concentration of ctDNA is reported, which allows clinicians to see historical results of the patient’s ctDNA concentration over time. Learn more at myriad.com/oncology/precise-mrd-test/.

(Press release, Myriad Genetics, MAY 27, 2026, View Source [SID1234666136])

InnoCare Announces Approval of Orelabrutinib in Australia

On May 27, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, reported that orelabrutinib (HIBRUKA) has been approved by the Therapeutic Goods Administration (TGA) in Australia, offering a new treatment option for patients with Mantle Cell Lymphoma (R/R MCL) in the region.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, "The approval of orelabrutinib in Australia marks another important milestone in InnoCare’s global footprint and brings a new treatment option to patients with lymphoma in the region. Beyond oncology, we are also advancing global clinical trials of orelabrutinib in autoimmune diseases."

MCL is a distinct subtype of B-cell non-Hodgkin’s lymphoma (NHL). It is an aggressive and currently incurable disease with rising incidence rate. Patients are often diagnosed at an advanced stage with limited treatment options and poor prognosis.

Orelabrutinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. With its high target selectivity, it minimizes off-target effects, thereby improving both safety and efficacy.

Orelabrutinib has been approved in Singapore for the treatment of patients with R/R MCL and R/R MZL (marginal zone lymphoma). In China, Orelabrutinib has been approved for the treatment of four lymphoma indications, all of which have been included in China’s National Reimbursement Drug List.

(Press release, InnoCare Pharma, MAY 27, 2026, View Source [SID1234666135])

Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics

On May 27, 2026 Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, reported the close of its seed financing. The close brings total capital raised to $6 million since the company’s founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.

Proceeds will support continued development of the company’s lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming, where mRNA-encoded gene combinations, delivered directly into the tumor, activate the immune system by inducing antigen-presenting function in tumor cells. This approach is designed to transform the immunosuppressive tumor microenvironment into a site of active immune priming, with the goal of generating systemic antitumor immune responses.

"Many solid tumors remain difficult to treat despite advances in immunotherapy," said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. "Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents."

"This is a first-in-class approach to a problem that kills 10 million people a year, built by founders who moved from concept to in vivo data in six months with unparalleled capital efficiency," said Colin Greenspon, co-founder and partner at Narya. "That’s the kind of team and science Narya was built to back."

Reprogram identifies and prioritizes therapeutic reprogramming candidates with CellRecodeX, its AI discovery engine. CellRecodeX integrates multiple biological foundation models and is designed to support candidate nomination and pipeline expansion across indications.

(Press release, Reprogram Biosciences, MAY 27, 2026, View Source [SID1234666134])

Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026

On May 27, 2026 Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, reported that it will present a trial-in-progress poster highlighting the Phase 1 trial design of CLIO-8221 at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (May 29-June 2) in Chicago. CLIO-8221 is a first-in-class dual-payload ADC currently in Phase 1 clinical development (NCT07300943) for HER2-expressing solid tumors.

"CLIO-8221 is the first program from Callio Therapeutics’ dual-payload ADC pipeline to enter the clinic, advancing our strategy to develop rationally designed payload combinations for hard-to-treat tumors," said Naomi Hunder, MD, Chief Medical Officer of Callio Therapeutics. "Developed with our proprietary linker technology and payload combination platform, CLIO-8221 is a first-in-class dual-payload ADC designed to deliver a topoisomerase 1 inhibitor and an ATR inhibitor directly to HER2-expressing tumors to address key mechanisms of resistance to existing HER2-targeted ADCs, including trastuzumab deruxtecan. With our Phase 1 trial now enrolling patients with advanced HER2-expressing solid tumors, we look forward to generating clinical data that will inform its potential as a differentiated treatment option."

"Patients with HER2-expressing solid tumors who progress on currently available HER2-targeted therapies continue to have limited treatment options," said Timothy A. Yap, MBBS, PhD, lead investigator at The University of Texas MD Anderson Cancer Center for the CLIO-8221 Phase 1 trial, and presenting author of the poster. "CLIO-8221 represents an innovative dual-payload approach to overcome resistance associated with existing HER2-targeted ADCs. This trial marks an important step in evaluating whether combining topoisomerase 1 and ATR inhibition within a single HER2-targeted ADC can expand treatment possibilities for patients with HER2-expressing solid tumors."

The Phase 1 clinical trial recruitment is ongoing in Australia and the United States, and the company plans to activate sites in China.

At ASCO (Free ASCO Whitepaper), Callio Therapeutics will present previously disclosed preclinical data (AACR 2026) that support the therapeutic potential of CLIO-8221 and the Phase 1 trial design:

By simultaneously delivering a topoisomerase 1 inhibitor (exatecan) and an ATR inhibitor (berzosertib), CLIO-8221 drives direct tumor cell killing at doses that also support a robust bystander effect, achieving superior in vivo efficacy compared to single-payload ADCs
CLIO-8221 demonstrated potent anti-tumor activity across varying HER2 expression levels and drove tumor regression after a single dose in both trastuzumab deruxtecan-sensitive and -insensitive models
CLIO-8221 exhibited a highly favorable safety profile; it was well-tolerated in non-human primates with no significant adverse effects observed at doses of 70 mg/kg (highest dose tested), establishing a No-Observed-Adverse-Effect Level (NOAEL) significantly higher than that of trastuzumab deruxtecan
Phase 1 of the study is a dose escalation with optional dose level expansions, and dose escalation may enroll across HER2-expressing cancers, including cancers that did not respond to or relapsed after trastuzumab deruxtecan treatment
Presentation details:

Poster/Abstract Title: Phase 1/2 Study of CLIO-8221, a HER2-targeted, dual-payload exatecan and ATR inhibitor antibody-drug conjugate (ADC) in patients with advanced HER2-expressing solid tumors
Poster Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Date & Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Location: McCormick Place, Hall A – Posters and Exhibits
Presenter: Timothy A. Yap, MBBS, PhD, The University of Texas MD Anderson Cancer Center
Abstract Number: TPS3162
Poster Board: 295b

The full abstract is available on the ASCO (Free ASCO Whitepaper) Annual Meeting website. The poster will be available on the ASCO (Free ASCO Whitepaper) website on May 30, 2026.

About CLIO-8221

HER2 is a clinically validated target for antibody-drug conjugates (ADCs), with multiple approved therapies demonstrating meaningful benefit across tumor types, however, most patients eventually progress on treatment despite retaining HER2 expression. Mechanistic resistance to cytotoxic payloads has emerged as a key reason for treatment failure. CLIO-8221 is a novel, first-in-class dual-payload ADC targeting HER2, designed to address this challenge.

CLIO-8221 delivers two mechanistically complementary payloads, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, directly to HER2-expressing tumors. While Topo1 inhibitors have shown strong clinical activity, activation of the DNA damage response following Topo1 inhibitor-induced replication stress represents a potential major driver of resistance. By simultaneously inhibiting Topo1 and blocking the DNA damage response through ATR inhibition, CLIO-8221 is engineered to overcome payload insensitivity and sensitize tumors to Topo1 inhibition. Developed using proprietary linker and ADC platform technologies, CLIO-8221 aims to maximize anti-tumor activity while reducing systemic toxicity, offering the potential for deeper and more durable responses in patients who have progressed on existing HER2-targeted therapies.

(Press release, Callio Therapeutics, MAY 27, 2026, View Source [SID1234666133])

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

On May 27, 2026 Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, reported that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will take place on Wednesday, June 3, 2026, at 4:20 p.m. ET.

A live webcast of the presentations may be accessed via the Investors section of the Aktis website at investors.aktisoncology.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.

(Press release, Aktis Oncology, MAY 27, 2026, View Source [SID1234666132])